Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Non-Current Assets (2020 - 2026)

RxSight filings provide 6 years of Non-Current Assets readings, the most recent being $24.4 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 1.56% to $24.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $98.8 million, a 13.12% increase, with the full-year FY2025 number at $24.4 million, down 1.56% from a year prior.
  • Non-Current Assets hit $24.4 million in Q4 2025 for RxSight, down from $24.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $25.1 million in Q2 2025 to a low of $13.9 million in Q3 2023.
  • Median Non-Current Assets over the past 5 years was $16.8 million (2022), compared with a mean of $19.0 million.
  • Biggest five-year swings in Non-Current Assets: fell 15.96% in 2023 and later soared 74.93% in 2024.
  • RxSight's Non-Current Assets stood at $16.4 million in 2021, then fell by 4.97% to $15.6 million in 2022, then decreased by 9.39% to $14.1 million in 2023, then soared by 74.93% to $24.7 million in 2024, then fell by 1.56% to $24.4 million in 2025.
  • The last three reported values for Non-Current Assets were $24.4 million (Q4 2025), $24.7 million (Q3 2025), and $25.1 million (Q2 2025) per Business Quant data.